PMID- 37591343
OWN - NLM
STAT- Publisher
LR  - 20231008
IS  - 1872-8227 (Electronic)
IS  - 0168-8227 (Linking)
VI  - 203
DP  - 2023 Sep
TI  - The role of weight control in the management of type 2 diabetes mellitus: 
      Perspectives on semaglutide.
PG  - 110881
LID - S0168-8227(23)00644-7 [pii]
LID - 10.1016/j.diabres.2023.110881 [doi]
AB  - Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are widely used to address 
      multiple aspects of type 2 diabetes mellitus (T2DM) management, including 
      glycaemic control, weight loss, and cardiovascular risk reduction. Semaglutide, a 
      well-established GLP-1 RA approved for T2DM treatment and weight management, 
      demonstrates marked efficacy in achieving these clinically important goals. The 
      American Diabetes Association (ADA) and the European Association for the Study of 
      Diabetes (EASD) consensus report emphasizes the importance of a holistic approach 
      to T2DM treatment, with weight control as a key component for improving patient 
      outcomes. Notably, semaglutide is mentioned in the consensus report as having 
      'very high' efficacy for both glucose lowering and weight loss in T2DM treatment. 
      Nevertheless, as has been observed with other weight-lowering drugs, weight loss 
      observed with semaglutide appears less profound in individuals with T2DM than in 
      those with obesity without T2DM, a phenomenon requiring further investigation. 
      The semaglutide safety and tolerability profiles are well established, and it is 
      approved in some countries to reduce cardiovascular risk in certain populations 
      with T2DM. Thus, semaglutide offers a well-established therapeutic option that 
      aligns well with guideline recommendations for T2DM management, emphasizing the 
      high importance of weight control and amelioration of other cardiometabolic risk 
      factors.
CI  - Copyright (c) 2023 Elsevier B.V. All rights reserved.
FAU - Kurtzhals, Peter
AU  - Kurtzhals P
AD  - Novo Nordisk A/S, Vandtaarnsvej 110-114 DK-2860, Soborg, Denmark. Electronic 
      address: pkur@novonordisk.com.
FAU - Flindt Kreiner, Frederik
AU  - Flindt Kreiner F
AD  - Novo Nordisk A/S, Vandtaarnsvej 110-114 DK-2860, Soborg, Denmark. Electronic 
      address: frfk@novonordisk.com.
FAU - Singh Bindra, Rubdeep
AU  - Singh Bindra R
AD  - Novo Nordisk A/S, Vandtaarnsvej 110-114 DK-2860, Soborg, Denmark. Electronic 
      address: rsib@novonordisk.com.
LA  - eng
PT  - Journal Article
DEP - 20230815
PL  - Ireland
TA  - Diabetes Res Clin Pract
JT  - Diabetes research and clinical practice
JID - 8508335
SB  - IM
OTO - NOTNLM
OT  - Cardiovascular risk
OT  - GLP-1 RA
OT  - Kidney protection
OT  - Semaglutide
OT  - Type 2 diabetes mellitus
OT  - Weight control
COIS- Declaration of Competing Interest The authors declare the following financial 
      interests/personal relationships which may be considered as potential competing 
      interests: Peter Kurtzhals reports a relationship with Novo Nordisk AS that 
      includes: employment and equity or stocks. Frederik Flindt Kreiner reports a 
      relationship with Novo Nordisk AS that includes: employment and equity or stocks. 
      Rubdeep Singh Bindra reports a relationship with Novo Nordisk AS that includes: 
      employment and equity or stocks.
EDAT- 2023/08/18 00:42
MHDA- 2023/08/18 00:42
CRDT- 2023/08/17 19:18
PHST- 2023/06/30 00:00 [received]
PHST- 2023/08/01 00:00 [revised]
PHST- 2023/08/13 00:00 [accepted]
PHST- 2023/08/18 00:42 [pubmed]
PHST- 2023/08/18 00:42 [medline]
PHST- 2023/08/17 19:18 [entrez]
AID - S0168-8227(23)00644-7 [pii]
AID - 10.1016/j.diabres.2023.110881 [doi]
PST - ppublish
SO  - Diabetes Res Clin Pract. 2023 Sep;203:110881. doi: 10.1016/j.diabres.2023.110881. 
      Epub 2023 Aug 15.